Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aaron Schuchart Insider Profile
4 Followers
Aaron Schuchart, CBO at Spyre Therapeutics, holds 0.00 shares in Lumos Pharma (Ticker: LUMO), holds 2.50K shares in Spyre Therapeutics (Ticker: SYRE).
Aaron Schuchart has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Aaron Schuchart's holdings
Insider Roles
CBO
Roles that Aaron Schuchart holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Sep 28, 2018 - Sep 28, 2019
Return:+20.10%
The most profitable trade made by Aaron Schuchart
Aaron Schuchart's Trading History
Spyre Therapeutics
Sep 28, 2018
CBO
Informative Sell
57.01K
$59.65K
Lumos Pharma
Dec 13, 2024
―
Uninformative Sell
―
$0.00
List of latest transactions for each holding click on a transaction to see Aaron Schuchart's performance on stock
You May Also Like
Aaron Schuchart insider profile FAQ
What is the percentage of profitable transactions made by Aaron Schuchart?
The percentage of profitable transactions made by Aaron Schuchart is ―.
What is the average return per transaction made by Aaron Schuchart?
The average return per transaction made by Aaron Schuchart is ―.
What stocks does Aaron Schuchart hold?
Aaron Schuchart holds: SYRE, LUMO stocks.
What was Aaron Schuchart’s latest transaction?
Aaron Schuchart latest transaction was an Uninformative Sell of ―.
What was Aaron Schuchart's most profitable transaction?
Aaron Schuchart’s most profitable transaction was an Informative Sell of SYRE stock on September 28, 2018. The return on the trade was 20.10%.
What is Aaron Schuchart's role in Spyre Therapeutics?
Aaron Schuchart's role in Spyre Therapeutics is CBO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.